SANIONA |
|
|||||
GENERAL INFORMATION |
|
|
Corporate description / mission
Saniona is a research and development company engaged in discovery and development of drugs for treatment of metabolic diseases, diseases of the central nervous system, autoimmune diseases and the treatment of pain. The company has a comprehensive portfolio of potential drug candidates in preclinical or clinical phase.
|
||||||||||||||||||
|
||||||||||||||||||
CATEGORIZATION | ||||||||||||||||||
|
|
|||||||||||||||||
SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES | ||||||||||||||||||
|
||||||||||||||||||
Description of products
TesofensineTesomet - T2D Tesomet - PWS NS2359 CAD-1883 SAN711 Boehringer Ingelheim program IK program Kv7 program Nicotinic a6 program. |
||||||||||||||||||
Technology used
Ion channel programs and technologies:GABA modulators K+ modulators Nicotinic modulators |
||||||||||||||||||
FINANCING DETAILS | ||||||||||||||||||
|
|
|||||||||||||||||
|
||||||||||||||||||
COLLABORATIONS, CLIENTS & MARKETS | ||||||||||||||||||
Partnering strategy / collaborations
Boehringer IngelheimCadent Therapeutics Productos Medix The Michael J. Fox Foundation TRC, University of Pennsylvania. |
||||||||||||||||||
![]()
|
||||||||||||||||||
![]() |
![]() |
|||||||||||||||||
|